Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
Abstract: The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.
Type:
Grant
Filed:
February 28, 2013
Date of Patent:
December 18, 2018
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Isabel Ribeiro Dos Santos, Michel Sournac
Abstract: The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome.
Type:
Application
Filed:
April 25, 2018
Publication date:
November 1, 2018
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Bruno LE GRAND, Didier JUNQUERO, Nicolas MONJOTIN
Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
Type:
Grant
Filed:
June 6, 2014
Date of Patent:
October 16, 2018
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
Abstract: Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.
Type:
Application
Filed:
October 3, 2016
Publication date:
October 4, 2018
Applicants:
PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Yoann MENON, Christophe LONG, François SAUTEL, Paola B. ARIMONDO
Abstract: The present invention relates to the use of a cosmetic composition intended for colouring the skin, said cosmetic composition including, as an active principle, an aqueous extract of gardenia.
Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
Type:
Grant
Filed:
July 6, 2015
Date of Patent:
August 14, 2018
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
Abstract: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
Type:
Application
Filed:
September 19, 2017
Publication date:
August 9, 2018
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Michel PEREZ, Ian RILATT, Marie LAMOTHE
Abstract: The present invention claims a chromone derivative and pharmaceutical compositions and combinations comprising a least the said derivative, which is a dopamine D3 receptor antagonist, for their use for the treatment of autism spectrum disorder.
Type:
Grant
Filed:
December 12, 2014
Date of Patent:
July 24, 2018
Assignee:
Pierre Fabre Medicament
Inventors:
Agnès Auclair, Paul Moser, Pierre Sokoloff
Abstract: The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome.
Type:
Grant
Filed:
October 31, 2014
Date of Patent:
May 29, 2018
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Bruno Le Grand, Didier Junquero, Nicolas Monjotin
Abstract: The present invention relates to (4-hydroxy-2-methyl-1,1-dioxido-2H-benzo[e][1,2]thiazine-3-yl)(naphthalen-2-yl)methanone or one of the salts thereof, pharmaceutically acceptable for use in the prevention and/or treatment of hepatic steatosis, including non-alcoholic steatohepatitis or one of the complications of same.
Type:
Application
Filed:
April 20, 2016
Publication date:
May 24, 2018
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Marie LAMOTHE, Didier JUNQUERO, Bruno LE GRAND
Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Abstract: The present invention relates to compounds of the following formula (I): and pharmaceutically acceptable salts and solvates thereof, their methods of preparation, their use as a drug, notably in the treatment of cancer, and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
September 19, 2014
Date of Patent:
April 24, 2018
Assignees:
PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
April 17, 2018
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
El Bachir Kaloun, Philippe Schmitt, Anna Kruczynski
Abstract: The present disclosure relates to a novel antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody.
Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
Type:
Application
Filed:
December 1, 2017
Publication date:
March 29, 2018
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
Abstract: The present invention relates to a process for obtaining a juice of fresh plants, characterized in that said fresh plants, with the exclusion of the seeds only, are subjected to a thermomechanical treatment consisting in extruding the fresh plants in an extruder, combined with a heat treatment which makes it possible to inactivate the endogenous enzymes and to preserve the molecules of compounds of interest in the native form thereof, in the absence of solvent, followed by a juice recovery operation.
Type:
Grant
Filed:
September 18, 2014
Date of Patent:
March 13, 2018
Assignees:
PIERRE FABRE DERMO-COSMETIQUE, PIERRE FABRE MEDICAMENT
Abstract: The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C1-C6) alkyl or —C(O)NH—(C1-C6) alkyl group. The invention also relates to the method for preparing said compound, to a pharmaceutical composition containing same, and to the use thereof as a drug, particularly for cancer treatment.
Type:
Grant
Filed:
January 24, 2014
Date of Patent:
January 23, 2018
Assignees:
PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
Abstract: The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the use of an antibody library for screening monoclonal antibodies, preferably human antibodies for treating cancer.
Abstract: The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.
Type:
Application
Filed:
September 2, 2015
Publication date:
October 5, 2017
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
El Bachir KALOUN, Serge GRISONI, Anna KRUCZYNSKI, Philippe SCHMITT